Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised,placebo-controlled,double blind trial in Norway
Restricted accessResearch articleFirst published online June, 1996
Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised,placebo-controlled,double blind trial in Norway
A multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy and safety of 4.5 and 9.0 MIU recombinant human interferon alfa-2a (Rof eron-A™) given thrice weekly in patients with relapsing-remittent multiple sclerosis is described. The patients are treated for 6 months followed by a 6 months drug-free period. The primary objective is to determine new disease activity analysed by monthly MRI with gadodiamide (GdDTPA-BMA, Omniscan™). The study is conducted at eight centers in Norway and is completed in January 1996.
1 Spielberger RT, Mick R, Ratain MJ, Golomb HM. (1994) Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986. Leuk Lymphoma14: S89–S93.
3 Ijichi S et al. (1995) Anti-viral immunomodulary effects of interferon-alfa on cultured lymphocytes from patients with human T lymphotropic virus type I-associated myelopathy (HAM/TSP). J Neuroimmunol61: 213–221.
4.
4 Knobler RL et al. (1984) Systemic alpha-interferon therapy of multiple sclerosis. Neurology34: 1273–1279.
5.
5 Camenga DL et al. (1986) Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol43: 1239–1246.
6.
6 AUSTIMS Research Group. (1989) Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry52: 566–574.
7.
7 Kastrukoff LF et al. (1990) Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology40: 479–486.
8.
8 Kinnunen E et al. (1993) Effects of recombinant alpha-2b-interferon therapy in patients with progressive MS. Acta Neurol Scand87: 457–460.
9.
9 Durelli L et al. (1994) Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology44: 406–413.
10.
10 Miller DH et al. (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg-Psychiatry54: 683–688.
11.
11 Kurtzke JF. (1993) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology33: 1444–1452.
12.
12 Sipe JC et al. (1984) A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology34: 1368–1372.
13.
13 Radosevich DM, Wetzler H, Wilson SM. (1994) Health Status Questionnaire 2.0: Scoring comparisons and reference data.Health Outcome Institute, Bloomongton, Minnesota.
14.
14 Goldberg D, Williams P. (1991) A user's guide to the General Health Questionnaire. NFER-Nelson, Berkshire.
15.
15 Nauta JJ, Thompson AJ, Barkhoff, Miller DH. (1994) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci122: 6–14.
16.
16 Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol13: 227–231.
